Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo Trial Ruxolitinib Cream Meets Endpoints in Phase 3 Vitiligo Trial

A topical formulation of the JAK inhibitor ruxolitinib produced statistically significant improvement in all primary and secondary outcomes relative to vehicle alone at 24 weeks.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news